Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BIBT-1011
- Development stage
- Unknown
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BIBT-1011 (also referred to as BIBT 1011 BS) is an oral small molecule drug developed as a selective inhibitor of factor Xa, a key enzyme in the coagulation cascade. By inhibiting factor Xa, the drug is designed to prevent thrombin generation and blood clot formation, making it potentially useful as an anticoagulant for conditions where thrombosis risk is elevated. The compound was developed by C.H. Boehringer Sohn AG & Co. KG and has been evaluated in phase 1 clinical trials for safety, pharmacodynamics, and pharmacokinetics in healthy subjects[1]. There are no approved indications or evidence of further development beyond early-phase studies.
02
Targets
F10 (Factor Xa)
Beyond the preview
Go deeper on BIBT-1011.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BIBT-1011.